Artificial Intelligence Clinical Genomics Interpretation Market Report 2026

The artificial intelligence clinical genomics interpretation market size has grown exponentially in recent years. It will grow from $1.74 billion in 2025 to $2.23 billion in 2026 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to increasing availability of genomic sequencing data, expansion of precision medicine initiatives, growing adoption of bioinformatics platforms, rising clinical use of genomic insights, early integration of ai in genomics workflows.

The artificial intelligence clinical genomics interpretation market size is expected to see exponential growth in the next few years. It will grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 28%. The growth in the forecast period can be attributed to increasing demand for personalized healthcare solutions, rising investments in genomic data analytics, expansion of oncology-focused genomics applications, growing adoption of cloud-based interpretation platforms, increasing focus on clinical-grade genomic reporting. Major trends in the forecast period include increasing adoption of AI-based variant interpretation tools, rising integration of genomics with clinical decision support, growing use of predictive modeling in genomic analysis, expansion of cloud-based genomics platforms, enhanced focus on personalized treatment planning.

The rising demand for personalized medicine is expected to drive the growth of the artificial intelligence clinical genomics interpretation market in the coming years. Personalized medicine involves tailoring diagnosis, treatment, and prevention strategies to an individual’s genetic, environmental, and lifestyle factors. This approach is gaining popularity because it enables more effective, patient-specific therapies, improving outcomes while minimizing adverse effects. AI clinical genomics interpretation supports personalized medicine by rapidly analyzing complex genomic data to identify precise treatment options, enhancing therapy effectiveness, and reducing trial-and-error approaches. For example, according to the Personalized Medicine Coalition in February 2024, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. This rising demand for patient-specific treatments is therefore expected to boost the AI clinical genomics interpretation market.

Major players in the AI clinical genomics interpretation market are emphasizing innovations that improve scalability for large genomic studies, enabling high-throughput data processing, more accurate genomic insights, and faster identification of biomarkers and therapeutic targets. Scalability allows AI systems to efficiently handle massive and complex genomic datasets without compromising speed or precision, a crucial factor as sequencing volumes and complexity grow. For instance, in December 2024, QIAGEN, a Germany-based life sciences company, introduced an AI-powered extension to its Ingenuity Pathway Analysis (IPA) platform, automating the interpretation of complex biological data. This enhancement leverages AI to identify key genes, pathways, and molecular networks involved in diseases and integrates QIAGEN’s Biomedical Knowledge Base, which contains hundreds of millions of AI-derived relationships, to deliver more accurate, data-driven insights.

In May 2025, GeneDx, a US-based provider of genomic diagnostic testing and precision medicine solutions, acquired Fabric Genomics for an undisclosed sum. Through this acquisition, GeneDx aims to enhance its AI-driven clinical genomics interpretation capabilities, particularly for rare diseases and neonatal genetic screening, thereby strengthening its technological leadership in precision medicine. Fabric Genomics is a US-based provider of AI-powered genomic data interpretation software and clinical decision support tools for healthcare providers and laboratories.

Major companies operating in the artificial intelligence clinical genomics interpretation market are F. Hoffmann-La Roche AG, NVIDIA Corporation, Illumina Inc., QIAGEN N.V., Tempus Labs Inc., GeneDx Inc., Freenome Inc., NantHealth Inc., SOPHiA GENETICS SA, Genomenon Inc., DNAnexus Inc., Lifebit Biotech Ltd., Deep Genomics Inc., SpeeDx Pty Ltd, PierianDx Inc., Genuity Science Inc., Karius Inc., FDNA Inc., SeqOne Genomics Inc., Nostos Genomics Inc.

North America was the largest region in the artificial intelligence clinical genomics interpretation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence clinical genomics interpretation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence clinical genomics interpretation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the AI clinical genomics interpretation market by increasing costs of imported sequencing equipment, high-performance computing infrastructure, data storage systems, and specialized analytics software. Hospitals, diagnostic laboratories, and research institutions in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces cost pressures on sequencing equipment exports. These tariffs are increasing implementation costs and delaying infrastructure upgrades. At the same time, they are supporting domestic genomics software development, regional data platform investments, and localized clinical genomics ecosystems.

The artificial intelligence clinical genomics interpretation market research report is one of a series of new reports that provides artificial intelligence clinical genomics interpretation market statistics, including artificial intelligence clinical genomics interpretation industry global market size, regional shares, competitors with a artificial intelligence clinical genomics interpretation market share, detailed artificial intelligence clinical genomics interpretation market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence clinical genomics interpretation industry. This artificial intelligence clinical genomics interpretation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence clinical genomics interpretation involves using AI-driven algorithms and computational models to analyze and interpret genomic data for clinical purposes. It facilitates the identification of genetic variants, prediction of disease risks, and supports personalized treatment decisions.

The primary components of AI clinical genomics interpretation include software and services. The software consists of AI-powered platforms and applications designed for automated analysis, interpretation, and reporting of complex clinical genomic data. These solutions can be implemented in cloud-based or on-premises settings. Their applications cover areas such as oncology, rare diseases, pharmacogenomics, infectious diseases, and more, while major end users include hospitals and clinics, research institutes, diagnostic laboratories, and other entities involved in clinical genomics.

The artificial intelligence clinical genomics interpretation market includes of revenues earned by entities by providing services such as variant interpretation services, pharmacogenomics interpretation services, and tumor genomic profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.